



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/833,327	04/12/2001	Samuel J. Danishefsky	2003080-0081(SK-719-Z)	3477

24280 7590 06/05/2002

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109

[REDACTED] EXAMINER

UNGAR, SUSAN NMN

ART UNIT	PAPER NUMBER
1642	

DATE MAILED: 06/05/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/833,327	Applicant(s) Danishefsky et al	
Examiner Ungar	Art Unit 1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Apr 12, 2001.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-74, 85-99, and 101-107 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims 1-74, 85-99, and 101-107 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) The translation of the foreign language provisional application has been received.

15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____	6) <input type="checkbox"/> Other: _____

Art Unit: 1642

1. Claims 1-74, 85-99, 100-107 are pending in the application and are currently under prosecution.

Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Anthony Caputa, Ph.D., Supervisory Patent Examiner at 703-308-3995. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

Group I. Claims 1-5, 31-38 and 101-107 are drawn to N3-heptasaccharides, derivatives thereof and methods of making these heptasaccharides, classified in class 536, subclass 123+.

Group II. Claims 6-16 are drawn to a method of preparing trisaccharide iodosulfonamide, classified in class 536, subclass 18.5+.

Group III. Claims 17-22 are drawn to a method of preparing a disaccharide stannane, classified in class 536, subclass 18.5+.

Group IV. Claims 23-30 and 53-60 are drawn to a method of preparing dissacharide ethylthioglycoside, classified in class 536, subclass 18.5+.

Group V. Claims 39-42 are drawn to a method of preparing a

heptasaccharide glycal diacetate intermediate, classified in class 536, subclass 18.5+.

Group VI. Claims 43-52 are drawn to a method of preparing a protected disaccharide, classified in class 536, subclass 18.5+.

Group VII. Claims 61-64 are drawn to a method of preparing a protected hexacasscharide, classified in class 536, subclass 18.5+.

Group VIII. Claims 65-74 are drawn to a method of preparing a nonasaccharide, classified in class 536, subclass 18.5+.

Group IX. Claims 87-99 are drawn to a method of treating a subject with epithelial cell cancer, classified in class 514, subclass 54+.

It is noted that claim 86 is dependent upon canceled claim 75 and cannot at this time be assigned to a group.

3. This application contains claims directed to the following patentably distinct species of the claimed invention: i.e. Oligosaccharides which can either by oligoglycosides where R is a H or an alkyl, aryl, or allyl moiety (class 536, subclass 4.1+) or glycopeptides/glyoproteins - where R is an amino acyl residue of a peptide or a protein (class 530/395+).

4. Applicant is required under 35 USC 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held allowable. Claims 1, 87 and 101 are generic.

5. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement and a listing of all claims readable thereon, including any claims subsequently added. An

Art Unit: 1642

argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

6. Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 47 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

7. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

8. The inventions are distinct, each from the other because of the following reasons:

Inventions II-IX are materially distinct methods which differ at least in objectives, method steps, reagents and/or dosages and/or schedules used, response variables, and criteria for success.

The inventions of Groups I and II-IV/VI-VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP 806.04, MPEP 808.01). In the instant case the different inventions (i.e. the method of making claims) have different effects (although a gycal is used in each of

Art Unit: 1642

the processes, the protection/deprotection and starting materials used all differ greatly).

Inventions I and V are related as mutually exclusive groups in an intermediate-final product relationship. Distinction is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP 806.04(b), 3rd paragraph), and the groups are patentably distinct (MPEP 806.04(h)). In the instant case, the intermediate product is deemed to be useful as a glycosylation agent and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants.

Inventions I and X are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (I) the process for using the product as claimed can be practiced with another materially different product or (ii) the product as claimed can be used in a materially different process of using that product [see *MPEP § 806.05(h)*]. In the instant case the process for using the product can be practiced with other complements such as lipopolysaccharides/lipid A with respect to antibody stimulation and other anti-cancer agents such as isotretinoin or etretinate.

9. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matter, restriction for examination purposes as indicated is proper.

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R.

Art Unit: 1642

§ 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

11. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

12. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (703) 305-2181. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

14. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (703) 308-3995. The fax phone number for this Art Unit is (703) 308-4242.

Art Unit: 1642

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Effective, February 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1642.


Susan Ungar
Primary Patent Examiner
June 3, 2002